"What" Series

What are immune checkpoints?

7 May 2024
2 min read

Immune checkpoints are a class of regulatory molecules in the immune system that are expressed on immune cells such as T cells and can modulate the intensity and duration of immune responses. Their main function is to prevent excessive activation of the immune system and avoid damage to the body's own tissues, and they are also called "immune sentinels."

In cancer immunology, immune checkpoint molecules play an important role. Tumor cells can exploit these molecules to suppress T cell activity, thereby evading attack by the immune system. For example, the binding of the programmed cell death receptor (PD-1) and its ligands (PD-L1 and PD-L2) can inhibit T cell activity, allowing tumor cells to survive and proliferate.

Other common immune checkpoints include CTLA-4, TIM-3, LAG-3, TIGHT, IDO, etc., which participate in the immune regulatory process through different mechanisms. The discovery and research of immune checkpoints have provided new perspectives and approaches for cancer treatment, particularly in the development and application of immune checkpoint inhibitors.

The mechanism of action of immune checkpoint inhibitors is primarily to block the binding of immune checkpoints to their ligands, relieving the immune function suppression caused by immune checkpoints and reactivating immune cells to exert anti-tumor effects. These inhibitors mainly target key immune checkpoint molecules such as CTLA-4, PD-1, and PD-L1, by activating the patient's immune response to effectively fight against cancer. For example, PD-1 inhibitors can bind to its ligands PD-L1/PD-L2 and transduce inhibitory signals, thereby reducing T cell proliferation and function. If tumor or microenvironmental cells express the ligands for PD-1, it facilitates immune evasion by tumor cells. Anti-PD-1/PD-L1 antibodies can block ligand-receptor binding and restore anti-tumor T cell activity. Similarly, CTLA-4 inhibitors can block the binding of CTLA-4 to B7 molecules, preventing T cell suppression and enhancing T cell activity. In this way, immune checkpoint inhibitors can promote the immune system's attack on tumor cells, helping to treat various types of cancer.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Fate Therapeutics Presents Preliminary FT522 Data for Autoimmune Diseases at ASGCT
Latest Hotspot
3 min read
Fate Therapeutics Presents Preliminary FT522 Data for Autoimmune Diseases at ASGCT
7 May 2024
Fate Therapeutics Reveals FT522 Early-Stage Data on Autoimmune Disorders in a New Abstract at the ASGCT Annual Conference.
Read →
What ADC-related progress will Innovent Biologics reveal at the ASCO conference?
Hot Spotlight
3 min read
What ADC-related progress will Innovent Biologics reveal at the ASCO conference?
7 May 2024
Innovent Biologics will present a poster demonstrating the safety and efficacy of IBI343 in patients with advanced pancreatic ductal adenocarcinoma or cholangiocarcinoma.
Read →
HanAll Biopharma Initiates Phase III VELOS-4 Trial of Tanfanercept for Dry Eye Syndrome
Latest Hotspot
3 min read
HanAll Biopharma Initiates Phase III VELOS-4 Trial of Tanfanercept for Dry Eye Syndrome
7 May 2024
HanAll Biopharma Launches Phase III Double-Blind, Placebo-Controlled VELOS-4 Study to Assess Tanfanercept in Treating Dry Eye Syndrome.
Read →
What is Diabetic Macular Edema?
"What" Series
2 min read
What is Diabetic Macular Edema?
7 May 2024
Diabetic macular edema (DME) is an eye complication related to diabetes, primarily affecting the macula region of the eye.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.